SGI-110
SGI-110 is a pharmaceutical drug with 8 clinical trials. Historical success rate of 100.0%.
Success Metrics
Based on 7 completed trials
Phase Distribution
Phase Distribution
5
Early Stage
3
Mid Stage
0
Late Stage
Highest Phase Reached
Phase 2Trial Status & Enrollment
100.0%
7 of 7 finished
0.0%
0 ended early
0
trials recruiting
8
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
SGI-110 in Combination With Carboplatin in Ovarian Cancer
SGI-110 in the Treatment of Advanced Hepatocellular Carcinoma (HCC)
A Phase II Study of SGI-110 in Philadelphia-Negative Myeloproliferative Neoplasms
SGI-110 in Combination With an Allogeneic Colon Cancer Cell Vaccine (GVAX) and Cyclophosphamide (CY) in Metastatic Colorectal Cancer (mCRC)
Phase 1 Study of SGI-110 in Patients With Acute Myeloid Leukemia
Clinical Trials (8)
SGI-110 in Combination With Carboplatin in Ovarian Cancer
SGI-110 in the Treatment of Advanced Hepatocellular Carcinoma (HCC)
A Phase II Study of SGI-110 in Philadelphia-Negative Myeloproliferative Neoplasms
SGI-110 in Combination With an Allogeneic Colon Cancer Cell Vaccine (GVAX) and Cyclophosphamide (CY) in Metastatic Colorectal Cancer (mCRC)
Phase 1 Study of SGI-110 in Patients With Acute Myeloid Leukemia
Phase I/II Study of SGI-110 With Irinotecan Versus Regorafenib or TAS-102 in Metastatic Colorectal Cancer
SGI-110 Plus Durvalumab/Tremelimumab in SCLC
A Study Investigating SGI-110 in Combination With Ipilimumab in Unresectable or Metastatic Melanoma Patients
All 8 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 8